<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00299416</url>
  </required_header>
  <id_info>
    <org_study_id>HSC- MS-02-188</org_study_id>
    <secondary_id>P50NS44277 project #1</secondary_id>
    <nct_id>NCT00299416</nct_id>
  </id_info>
  <brief_title>Caffeinol Hypothermia Protocol</brief_title>
  <official_title>Combined Neuroprotective Modalities Coupled With Thrombolysis in Acute Ischemic Stroke: A Pilot Study of Caffeinol and Mild Hypothermia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Caffeinol is a combination of caffeine and alcohol. The amount given is about the same as 1-2
      glasses of wine and 3-4 cups of coffee. The patient receives a one time dose given over two
      hour while being cooled to 34.5 C.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Symptomatic Intracerebral Hemorrhage</measure>
    <time_frame>from pre-dosage to 90 day followup</time_frame>
    <description>Symptomatic intracerebral hemorrhages were measured by a full NIHSS(National Institute of Health Stroke Scale) prior to caffeinol &amp; hypothermia,at the end of hypothermia &amp; rewarming, 24 hrs after stroke onset, daily during hospitalization,&amp; at the 90 day follow-up visit. In addition, modified NIHSS were done hourly during the 24 hr hypothermia period &amp; 12 hr rewarming period. At the end of rewarming an MRI was obtained to verify if hemorrhages or neurologic deteriorations were present.NIHSS scores severity of stroke on 11 items;more points given for greater deficiencies(range 0-42,0=normal)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Catheter Related Complications During Hypothermia &amp; Rewarming</measure>
    <time_frame>over 36 hour period</time_frame>
    <description>Catheter-related complications assessed whether participants had bleeding (major hemorrhaging) that required a blood transfusion, this was determined by labs. Participants were monitored for infections every hour during vital signs in the 24 hour hypothermia phase and 12 hour rewarming phase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Cardiorespiratory Failure</measure>
    <time_frame>every 30 minutes during hypothermia induction</time_frame>
    <description>The possibility of cardiorespiratory failure was monitored every 30 minutes during the 24 hour hypothermia period based on vitals signs and oxygen saturation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Feasibility: Time Required to Reach the Target Core Temperature or Lowest Tolerated Temperature, Stability of Patient Temperature, Control of Rewarming,</measure>
    <time_frame>rewarming over 12 hours until 36.5C has been achieved</time_frame>
    <description>Hypothermia will be maintained for 24 hours, afterward, the patient will be rewarmed, gradually, over 12 hours to 36.5C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achievement of Therapeutic Serum Ethanol and Caffeine Levels, and Amount of Sedation Needed to Suppress Shivering.</measure>
    <time_frame>rewarming over 12 hours until 36.5C has been achieved</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: NIHSS &lt; 2 at 24 Hours, Modified Rankin Scale (mRS) &lt; 2 at 3 Months, NIHSS &lt; 2 at 3 Months, and Length of Hospital and ICU Stay.</measure>
    <time_frame>90 days</time_frame>
    <description>NIHSS score of ≤ 2 24 hours after stroke onset modified Rankin Scale (mRS) &lt; 2 at 90 day followup NIHSS score of ≤ 2 at daily duration of hospitalization and ICU stay and 90 day follow up.</description>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeinol</intervention_name>
    <description>Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hypothermia</intervention_name>
    <description>External or internal cooling for 24 hours and rewarming over 12 hours.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-80 years

          2. Clinical presentation of acute ischemic stroke

          3. Computed tomography (CT) scan compatible with acute ischemic stroke.

          4. Time to caffeinol treatment &lt; 240 minutes from stroke onset.

          5. Time to hypothermia initiation &lt; 300 minutes from stroke onset.

          6. Presumed cortical location of stroke (must have at least on sign such as aphasia,
             neglect, visual field cut)

          7. National Institutes of Health Stroke Scale (NIHSS) &gt; 8 at time of each treatment.

          8. Tissue plasminogen activator (TPA) treated patients must meet all established criteria
             for TPA.

        Exclusion Criteria:

          1. Etiology other than ischemic stroke.

          2. Item 1a on NIHSS &gt; 1

          3. Signs/symptoms of subcortical, brainstem or cerebellar stroke.

          4. Symptoms resolving or NIHSS &lt; 8 at time of each treatment.

          5. NIHSS &gt; 20 if right hemisphere or &gt;25 if left hemisphere

          6. Known alcoholic

          7. Clinical or laboratory evidence of alcohol intoxication.

          8. Historical evidence of exogenous caffeine exposure beyond daily consumption of coffee
             or soft drinks.

          9. Known hematologic dyscrasias that affect thrombosis.

         10. Comorbid conditions likely to complicate therapy:

               1. End-stage cardiomyopathy

               2. Uncompensated or clinically significant arrhythmia

               3. Myopathy

               4. Liver disease

               5. History of pelvic or abdominal mass likely to compress inferior vena cava.

               6. End-stage AIDS

               7. History of clinically significant gastrointestinal (GI) bleeding

               8. Impaired renal function with creatinine clearance, 50 ml/min

         11. Intracerebral / intraventricular hemorrhage

         12. Systolic blood pressure (SBP) &gt; 210 or &lt; 100; diastolic blood pressure (DBP) &gt; 100 or
             &lt; 50 mmHg

         13. Severe coagulopathy

         14. Pregnancy

         15. Use of monoamine oxidase inhibitor (MAOI),serotonin-specific reuptake inhibitor (SSRI)
             or Tricyclic Antidepressants (TCA) within the preceding 2 weeks

         16. Known history of epilepsy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C. Grotta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Hermann Hospital - Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.houstonstroke.com</url>
    <description>Introduction of the staff and facility on the stroke team, types of strokes, treatment, risk factors, recovery clinical trials, and contact information.</description>
  </link>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2006</study_first_submitted>
  <study_first_submitted_qc>March 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2006</study_first_posted>
  <results_first_submitted>August 16, 2010</results_first_submitted>
  <results_first_submitted_qc>April 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 3, 2011</results_first_posted>
  <last_update_submitted>April 5, 2011</last_update_submitted>
  <last_update_submitted_qc>April 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>James C. Grotta, MD-</name_title>
    <organization>UT- Houston Health Science Center, Department of Neurology</organization>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Nonhemorrhagic</keyword>
  <keyword>hypothermia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patient/&amp; or family was approached by one of the investigators in the Emergency Department in order to obtain informed consent.</recruitment_details>
      <pre_assignment_details>Open label pilot trial; Caffeinol Arm</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Caffeinol</title>
          <description>Caffeinol will be administered over a 2 hour infusion period. Dosage of caffeinol is based on on-going dose escalation trials and based on the patients weight. Currently the dosage is: ethanol 10% (0.4gm/kg) and caffeine 9 mg/kg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Caffeinol</title>
          <description>Caffeinol will be administered over a 2 hour infusion period. Dosage of caffeinol is based on on-going dose escalation trials and based on the patients weight. Currently the dosage is: ethanol 10% (0.4gm/kg) and caffeine 9 mg/kg.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Symptomatic Intracerebral Hemorrhage</title>
        <description>Symptomatic intracerebral hemorrhages were measured by a full NIHSS(National Institute of Health Stroke Scale) prior to caffeinol &amp; hypothermia,at the end of hypothermia &amp; rewarming, 24 hrs after stroke onset, daily during hospitalization,&amp; at the 90 day follow-up visit. In addition, modified NIHSS were done hourly during the 24 hr hypothermia period &amp; 12 hr rewarming period. At the end of rewarming an MRI was obtained to verify if hemorrhages or neurologic deteriorations were present.NIHSS scores severity of stroke on 11 items;more points given for greater deficiencies(range 0-42,0=normal)</description>
        <time_frame>from pre-dosage to 90 day followup</time_frame>
        <population>Number of participants were determined by intention to treat. We did not use any imputation technique.</population>
        <group_list>
          <group group_id="O1">
            <title>Caffeinol</title>
            <description>Caffeinol will be administered over a 2 hour infusion period. Dosage of caffeinol is based on on-going dose escalation trials and based on the patients weight. Currently the dosage is: ethanol 10% (0.4gm/kg) and caffeine 9 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Symptomatic Intracerebral Hemorrhage</title>
          <description>Symptomatic intracerebral hemorrhages were measured by a full NIHSS(National Institute of Health Stroke Scale) prior to caffeinol &amp; hypothermia,at the end of hypothermia &amp; rewarming, 24 hrs after stroke onset, daily during hospitalization,&amp; at the 90 day follow-up visit. In addition, modified NIHSS were done hourly during the 24 hr hypothermia period &amp; 12 hr rewarming period. At the end of rewarming an MRI was obtained to verify if hemorrhages or neurologic deteriorations were present.NIHSS scores severity of stroke on 11 items;more points given for greater deficiencies(range 0-42,0=normal)</description>
          <population>Number of participants were determined by intention to treat. We did not use any imputation technique.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Feasibility: Time Required to Reach the Target Core Temperature or Lowest Tolerated Temperature, Stability of Patient Temperature, Control of Rewarming,</title>
        <description>Hypothermia will be maintained for 24 hours, afterward, the patient will be rewarmed, gradually, over 12 hours to 36.5C.</description>
        <time_frame>rewarming over 12 hours until 36.5C has been achieved</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Achievement of Therapeutic Serum Ethanol and Caffeine Levels, and Amount of Sedation Needed to Suppress Shivering.</title>
        <time_frame>rewarming over 12 hours until 36.5C has been achieved</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: NIHSS &lt; 2 at 24 Hours, Modified Rankin Scale (mRS) &lt; 2 at 3 Months, NIHSS &lt; 2 at 3 Months, and Length of Hospital and ICU Stay.</title>
        <description>NIHSS score of ≤ 2 24 hours after stroke onset modified Rankin Scale (mRS) &lt; 2 at 90 day followup NIHSS score of ≤ 2 at daily duration of hospitalization and ICU stay and 90 day follow up.</description>
        <time_frame>90 days</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Catheter Related Complications During Hypothermia &amp; Rewarming</title>
        <description>Catheter-related complications assessed whether participants had bleeding (major hemorrhaging) that required a blood transfusion, this was determined by labs. Participants were monitored for infections every hour during vital signs in the 24 hour hypothermia phase and 12 hour rewarming phase.</description>
        <time_frame>over 36 hour period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caffeinol</title>
            <description>Caffeinol will be administered over a 2 hour infusion period. Dosage of caffeinol is based on on-going dose escalation trials and based on the patients weight. Currently the dosage is: ethanol 10% (0.4gm/kg) and caffeine 9 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Catheter Related Complications During Hypothermia &amp; Rewarming</title>
          <description>Catheter-related complications assessed whether participants had bleeding (major hemorrhaging) that required a blood transfusion, this was determined by labs. Participants were monitored for infections every hour during vital signs in the 24 hour hypothermia phase and 12 hour rewarming phase.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cardiorespiratory Failure</title>
        <description>The possibility of cardiorespiratory failure was monitored every 30 minutes during the 24 hour hypothermia period based on vitals signs and oxygen saturation.</description>
        <time_frame>every 30 minutes during hypothermia induction</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Caffeinol</title>
            <description>Caffeinol will be administered over a 2 hour infusion period. Dosage of caffeinol is based on on-going dose escalation trials and based on the patients weight. Currently the dosage is: ethanol 10% (0.4gm/kg) and caffeine 9 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiorespiratory Failure</title>
          <description>The possibility of cardiorespiratory failure was monitored every 30 minutes during the 24 hour hypothermia period based on vitals signs and oxygen saturation.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over the duration of the study (2003-2009)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Caffeinol</title>
          <description>Caffeinol will be administered over a 2 hour infusion period. Dosage of caffeinol is based on on-going dose escalation trials and based on the patients weight. Currently the dosage is: ethanol 10% (0.4gm/kg) and caffeine 9 mg/kg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombotic thrombocytopenia</sub_title>
                <description>Attributed to clopidrogrel and required treatment with plasmapheresis</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecysitits</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Three patients died (SAE unrelated to study interventions):
(1) symptomatic hemorrhage due to severity of stroke
(1) malignant edema/ herniation
(1) unrelated medical condition (withdrawal of care requested by family)</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Neuroworsening</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Parenchymal hemorrhage</sub_title>
                <description>3 symptomatic
1 asymptomatic</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Reduced respiratory drive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated WBC</sub_title>
                <description>No fever/ symptoms; resolved without treatment.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Low Hgb/ Hct</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Abnormal Labs (chem.)</sub_title>
                <description>(1)Low K+ - replaced/ resolved
(1)Elevated K+ - treated
(1)Elevated Mg - asymptomatic/ resolved</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated CK</sub_title>
                <description>Elevated Ck noted -asymptomatic/ resolved</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <description>(1) A. fib
(1)A. fib with AV block</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated Amylase</sub_title>
                <description>Elevated amylase noted:Asymptomatic/resolved.</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>(2)UTI treated/ resolved.
GNR central line infection. Line removed/ antibiotic added. Resolved.
MRSA pneumonia treated.
Possible pneumonia treated with naficillin/ ceftin.
Pneumonia treated with antibiotics. Resolved.</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Asymptomatic hemorrhagic transformation</sub_title>
                <description>Noted/ resolved</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <description>(1)Treated with lasix and nebulizer treatment. Resolved.
(1)Shortness of breath, oxygen saturation 87%, infiltrates on CXR. Treated with BiPAP &amp; lasix</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Sedation</sub_title>
                <description>Sedation noted:
(2)Demerol dose was reduced/held. Sedation resolved.
(2)Acidosis secondary to sedation. Treated/ resolved.</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Device failure</sub_title>
                <description>Cooling machine failure (3) Icy catheter tubing leak (1)</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James C. Grotta, MD</name_or_title>
      <organization>UT-Houston Health Science Center, Department of Neurology</organization>
      <phone>713-500-7088</phone>
      <email>james.c.grotta@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

